Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Analyzing the PAH treatment landscape and the potential of KER-012 from Keros Therapeutics and Seralutinib (GB002) from Gossamer Bio

Ticker(s): GOSS, KROS

Who's the expert?

Institution: Arizona Pulmonary Specialists

Director of the Pulmonary Vascular and Advanced Lung Disease program at Arizona pulmonary specialists, a nationally recognized center of excellence.
Currently manages over 400 patients with pulmonary arterial hypertension.
Directs a large clinical research program focusing on pulmonary hypertension and pulmonary fibrosis and caring for critically ill patients.

Interview Goal

This call will feature a discussion on the current treatment landscape for Pulmonary arterial hypertension and also analyze the available data on two upcoming therapies; KER-012 from Keros Therapeutics and Seralutinib (GB002) from Gossamer Bio

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.